The United States Patent and Trademark Office recently issued patent number 7,056,698 entitled: Nucleic Acids Encoding Interleukin-9 Receptor Variants, to Genaera Corporation.
The patent will expire on November 2018 which relates to the diagnosis, treatment and methods for discovery of new therapeutics for atopic asthma and related disorders based on variants of interleukin-9 (IL-9) receptor.
IL-9 has been associated with symptoms of asthma including mucous production, lung infiltration of inflammatory cells, and IgE (an immune globulin associated with allergic disease) production.
Read more at Genaera press release (a pdf file)."The protection provided by this patent further strengthens our intellectual property position around the naturally occurring variants of the IL-9 receptor," said Jack Armstrong, President and Chief Executive Officer.
"This receptor is central to the development of diagnostic methods, research tools, and most importantly, new therapies for atopic asthma, allergy and other IL-9 related diseases. We are delighted to have secured additional value for our research efforts in allergy and respiratory diseases."
Comment Preview